References
- Moreland L. W., Baumgartner S. W., Schiff M. H., Tyndall E. A., Fleischman R. M., Weaver A. L., et al. Treatment of rheumatoid arthritis with recombinant tumor necrosis factor receptor (p75)‐Fc fusion protein. N Engl J Med 1997; 337: 141–7
- Federico G., Rigante D., Pugliese A. L., Ranno O., Catania S., Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 2003; 32: 312–14
- The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomised, placebo‐controlled multicenter study. Neurology 1999; 53: 457–65
- Kunzmann S., Warmuth‐Metz M., Girschick H. J. Cerebral demyelination in association with TNF‐inhibition therapy in a 5‐year‐old girl with aseptic meningitis as the first symptom of Still's disease. Scand J Rheumatol 2005; 34: 76–8
- Wyeth‐Ayerst Laboratories and Immunex Inc, [Revised package insert for etanercept.]
- Mohan N., Edwards E. T., Cupps T. R., Oliveiro P. J., Sandberg G., Crayton H., et al. Demyelination occurring during anti‐tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–9
- Sicotte N. L., Voskuhl R. R. Onset of multiple sclerosis associated with anti‐TNF therapy. Neurology 2001; 57: 1885–8
- Robinson W. H., Genovese M. C., Moreland L. W. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. By what mechanisms could tumor necrosis factor α antagonists improved rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum 2001; 44: 1977–83
- Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
- Schwid S. R., Noseworthy J. H. Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss. Neurology 1999; 53: 444–5